Barclays
ARLZ

Barclays’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Barclays’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-100
Closed – – 7725
2018
Q2 		$0 Sell
100
-31,142
-100% -$25.5K ﹤0.01% 7657
2018
Q1 		$47K Sell
31,242
-7,100
-19% -$12.4K ﹤0.01% 5952
2017
Q4 		$54K Buy
+38,342
New +$62.9K ﹤0.01% 5715
2017
Q3 		– Sell
-400
Closed -$1K – 7337
2017
Q2 		$1K Sell
400
-31,829
-99% -$46K ﹤0.01% 6598
2017
Q1 		$69K Buy
32,229
+29,976
+1,330% +$113K ﹤0.01% 5152
2016
Q4 		$9K Buy
+2,253
New +$10.7K ﹤0.01% 5965
2016
Q3 		– Sell
-3,713
Closed -$12K – 7103
2016
Q2 		$12K Buy
+3,713
New +$14K ﹤0.01% 5490

Other funds holding ARLZ

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Barclays's ARLZ Position: Q3 2018 in Review

Barclays sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2018, closing a stake of 100 shares.

Barclays first reported a position in ARLZ in Q2 2016 and held it in 7 quarters. The position peaked at $69K in Q1 2017. 4 funds tracked by Wall St. Rank hold ARLZ as of Q3 2018.

  • Barclays reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
  • Barclays sold 100 Aralez Pharmaceuticals Inc. shares in Q3 2018.
  • Barclays first reported a position in Aralez Pharmaceuticals Inc. in Q2 2016 and held it in 7 quarters.
  • Barclays's Aralez Pharmaceuticals Inc. position peaked at $69K in Q1 2017.
  • 4 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2018.

Based on Barclays's 13F filing for Q3 2018, filed 14 Nov 2018.